IL113261A0 - Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction - Google Patents

Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction

Info

Publication number: IL113261A0
Authority: IL; Israel
Prior art keywords: receptor; present; beta; alpha; extracellular matrix
Prior art date: 1989-09-01

Application number

IL11326195A

Other languages

English (en)

Original Assignee

Hutchinson Fred Cancer Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-01

Filing date

1995-04-05

Publication date

1995-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL113261(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-04-05 Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res

1995-07-31 Publication of IL113261A0 publication Critical patent/IL113261A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

IL11326195A 1989-09-01 1995-04-05 Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction IL113261A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40238989A	1989-09-01	1989-09-01
IL9550195		1995-04-05

Publications (1)

Publication Number	Publication Date
IL113261A0 true IL113261A0 (en)	1995-07-31

Family

ID=23591680

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL95501A IL95501A (en)	1989-09-01	1990-08-27	Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
IL11326190A IL113261A (en)	1989-09-01	1990-08-27	Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
IL11326195A IL113261A0 (en)	1989-09-01	1995-04-05	Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
IL95501A IL95501A (en)	1989-09-01	1990-08-27	Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
IL11326190A IL113261A (en)	1989-09-01	1990-08-27	Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides

Country Status (19)

Country	Link
EP (2)	EP0489837B2 (xx)
JP (1)	JP3357359B2 (xx)
KR (1)	KR100188459B1 (xx)
AT (1)	ATE253642T1 (xx)
AU (1)	AU654657B2 (xx)
CA (1)	CA2065292C (xx)
DD (1)	DD297562A5 (xx)
DE (3)	DE122006000044I2 (xx)
DK (1)	DK0489837T4 (xx)
ES (1)	ES2210225T5 (xx)
FI (2)	FI116793B (xx)
GR (2)	GR1001161B (xx)
IE (2)	IE903169A1 (xx)
IL (3)	IL95501A (xx)
LU (1)	LU91273I2 (xx)
NL (1)	NL300240I2 (xx)
NZ (1)	NZ235131A (xx)
PT (1)	PT95180A (xx)
WO (1)	WO1991003252A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5730978A (en) *	1989-09-01	1998-03-24	Fred Hutchinson Cancer Research Center	Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en)	1989-09-01	2007-07-03	Fred Hutchinson Cancer Research Center	Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) *	1989-09-27	2000-03-07	Elan Pharmaceuticals, Inc.	Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5610148A (en) *	1991-01-18	1997-03-11	University College London	Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) *	1991-01-18	1997-05-13	University College London	Depot formulations
AU3420693A (en) *	1991-12-24	1993-07-28	Fred Hutchinson Cancer Research Center	Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
CA2127462C (en) *	1992-01-13	1999-03-23	Roy R. Lobb	Treatment for asthma
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en)	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) *	1992-07-26	1996-05-14	Yeda Res & Dev	Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
US5843438A (en)	1992-11-13	1998-12-01	Board Of Regents University Of Washington	Peripheralization of hematopoietic stem cells
CA2155303C (en) †	1993-02-09	2010-04-20	Linda C. Burkly	Treatment for insulin dependent diabetes
WO1994021818A1 (en) †	1993-03-18	1994-09-29	N.V. Innogenetics S.A.	Process for typing hla-b using specific primers and probes sets
ZA947006B (en) *	1993-09-15	1995-05-02	Univ Emory	Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
AU693143B2 (en) *	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) *	1993-12-06	1998-10-13	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) *	1993-12-06	1999-08-10	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5770573A (en) *	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en)	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
EP1759709B1 (en) *	1994-01-25	2013-02-27	Elan Pharmaceuticals Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
FR2724393A1 (fr) *	1994-09-12	1996-03-15	Inst Nat Sante Rech Med	Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (en) *	1996-03-22	1997-10-02	Kao Corporation	External skin-care composition
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP3173426A1 (en)	2002-02-25	2017-05-31	Biogen MA Inc.	Administration of agents for the treatment of inflammation
US7125650B2 (en)	2004-07-20	2006-10-24	Roberts David H	Method for bump exposing relief image printing plates
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR20230021758A (ko)	2011-05-02	2023-02-14	밀레니엄 파머슈티컬스 인코퍼레이티드	항-α4β7 항체에 대한 제형
EP4597110A3 (en) *	2024-02-05	2025-09-10	Universita' degli studi di Brescia	Hypermobile ehlers-danlos syndrome, hypermobility spectrum disorders and osteoarthritis plasma markers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4578079A (en) *	1982-08-04	1986-03-25	La Jolla Cancer Research Foundation	Tetrapeptide
WO1990008833A1 (en) *	1989-02-02	1990-08-09	Massachusetts Institute Of Technology	Expression of recombinant fibronectin in genetically engineered cells

1990
- 1990-08-27 IL IL95501A patent/IL95501A/xx active IP Right Grant
- 1990-08-27 IL IL11326190A patent/IL113261A/en active IP Right Grant
- 1990-08-28 GR GR900100648A patent/GR1001161B/el not_active IP Right Cessation
- 1990-08-28 GR GR930100041A patent/GR1001372B/el not_active IP Right Cessation
- 1990-08-31 IE IE316990A patent/IE903169A1/en active IP Right Review Request
- 1990-08-31 EP EP90913598.0A patent/EP0489837B2/en not_active Expired - Lifetime
- 1990-08-31 DE DE122006000044C patent/DE122006000044I2/de active Active
- 1990-08-31 PT PT95180A patent/PT95180A/pt not_active Application Discontinuation
- 1990-08-31 ES ES90913598.0T patent/ES2210225T5/es not_active Expired - Lifetime
- 1990-08-31 WO PCT/US1990/004978 patent/WO1991003252A1/en active IP Right Grant
- 1990-08-31 DE DE1990634116 patent/DE122006000044I1/de active Pending
- 1990-08-31 AT AT90913598T patent/ATE253642T1/de active
- 1990-08-31 CA CA002065292A patent/CA2065292C/en not_active Expired - Lifetime
- 1990-08-31 DE DE69034116.4T patent/DE69034116T3/de not_active Expired - Lifetime
- 1990-08-31 NZ NZ235131A patent/NZ235131A/xx unknown
- 1990-08-31 AU AU63542/90A patent/AU654657B2/en not_active Expired
- 1990-08-31 IE IE20040028A patent/IE20040028A1/en not_active IP Right Cessation
- 1990-08-31 EP EP20030017578 patent/EP1366769A1/en not_active Withdrawn
- 1990-08-31 DK DK90913598.0T patent/DK0489837T4/da active
- 1990-08-31 JP JP51276390A patent/JP3357359B2/ja not_active Expired - Lifetime
- 1990-08-31 KR KR1019920700621A patent/KR100188459B1/ko not_active Expired - Fee Related
- 1990-09-03 DD DD90343788A patent/DD297562A5/de unknown
1992
- 1992-02-28 FI FI920899A patent/FI116793B/fi active IP Right Grant
1995
- 1995-04-05 IL IL11326195A patent/IL113261A0/xx unknown
2005
- 2005-09-21 FI FI20050941A patent/FI118842B/fi active IP Right Grant
2006
- 2006-08-10 LU LU91273C patent/LU91273I2/fr unknown
- 2006-08-11 NL NL300240C patent/NL300240I2/nl unknown

Also Published As

Publication number	Publication date
ES2210225T3 (es)	2004-07-01
EP0489837B2 (en)	2013-11-13
DE69034116D1 (de)	2003-12-11
IE20040028A1 (en)	2004-05-05
WO1991003252A1 (en)	1991-03-21
EP0489837A1 (en)	1992-06-17
KR100188459B1 (ko)	1999-06-01
DD297562A5 (de)	1992-01-16
IL113261A (en)	1996-10-16
DK0489837T3 (da)	2004-03-01
CA2065292C (en)	2001-05-29
PT95180A (pt)	1991-05-22
NL300240I1 (nl)	2006-10-02
DK0489837T4 (da)	2013-11-18
EP0489837A4 (en)	1993-06-16
AU654657B2 (en)	1994-11-17
DE69034116T3 (de)	2014-06-18
DE122006000044I1 (de)	2007-04-19
GR900100648A (en)	1992-01-20
DE122006000044I2 (de)	2011-01-13
LU91273I2 (fr)	2006-10-10
AU6354290A (en)	1991-04-08
JPH05503070A (ja)	1993-05-27
CA2065292A1 (en)	1991-03-02
IE903169A1 (en)	1991-03-13
KR920703086A (ko)	1992-12-17
FI20050941L (fi)	2005-09-21
FI118842B (fi)	2008-04-15
IL95501A (en)	1997-04-15
EP0489837B1 (en)	2003-11-05
NZ235131A (en)	1993-03-26
FI116793B (fi)	2006-02-28
EP1366769A1 (en)	2003-12-03
FI920899A0 (fi)	1992-02-28
NL300240I2 (nl)	2007-03-01
DE69034116T2 (de)	2004-08-26
ES2210225T5 (es)	2014-02-04
JP3357359B2 (ja)	2002-12-16
GR1001372B (el)	1993-10-29
ATE253642T1 (de)	2003-11-15
GR1001161B (el)	1993-05-24

Publication	Publication Date	Title
EP0489837A4 (en)	1993-06-16	Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction
Oppenheimer-Marks et al.	1990	Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell.
Henocq et al.	1988	Skin eosinophilia in atopic patients
KR950700333A (ko)	1995-01-16	개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
DE3586619D1 (de)	1992-10-15	Haematologische zusammensetzungen als referenz fuer drei populationen von leukocyten, verfahren zu deren herstellung und deren verwendung in ganzbluttestverfahren.
IL71621A0 (en)	1984-07-31	Use of alpha factor sequences in yeast expression systems
ATE425252T1 (de)	2009-03-15	Ligand (act-4-l) für einen rezeptor auf der oberfläche aktivierter cd4+ t - zellen
IT1147852B (it)	1986-11-26	Impianto di avviso di prossimita' del suolo per aerei,con commutazione di modo in base al tempo
IT8521468A0 (it)	1985-07-08	Procedimento per ottenere interferon leucocitario alfa-2dell'uomo.
DE3766514D1 (de)	1991-01-17	1,2,3,4-tetrahydro-6-substituierte-4-aryl(oder heterocyclo)-3-substituierte-2-thioxo(oder oxo)-5-pyrimidincarboxylsaeuren und -ester.
FI883351A0 (fi)	1988-07-14	Diagnostisk metod foer paovisande av stoerningar i rna-as l.
Fabris et al.	1999	Fibrogenesis serum markers in patients with chronic hepatitis C treated with α-IFN
Li et al.	1996	Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro
BE876204A (fr)	1979-11-12	Composition en vue de reduire le taux de phenylalanine dans le sang, et son procede d'utilisation
ZA843060B (en)	1984-11-28	Use of alpha factor sequences in yeast expression systems
DE790059T1 (de)	1998-03-12	Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung
FR2643023B1 (fr)	1992-07-31	Incrustation d'un metal non ferreux dans un support en roches naturelles ou verre
Hanson	1983	Volcanism, plutonism, and sedimentation in a late Devonian Submarine Island-arc setting, Northern Sierra Nevada, California[Ph. D. Thesis]
银剑钊 et al.	1995	K-Ar isotope evidence for age of the first and only independent tellurium deposit
RU95111745A (ru)	1997-11-27	Способ прогнозирования позднего гестоза
FR2640385B1 (fr)	1991-02-08	Nouveau procede de dosage de l'heparine et son utilisation dans les trousses de dosage
Lyublinskaya et al.	1984	Solid-phase synthesis of biospecific sorbent for aminopeptidases.
IT8882571A0 (it)	1988-07-18	Supporto per posateria particolarmente per scolare i mestoli
AU6696181A (en)	1982-08-12	Dishwasher with dishwashing compartment and counterweight
KR900701834A (ko)	1990-12-04	사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법